Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

All Publications

Publications for all Oxford Principal Investigators within the CAMS Oxford Institute are included here, please use the search functions for publications related to specific Principal Investigators.

comBO: A combined human bone and lympho-myeloid bone marrow organoid for pre-clinical modelling of haematopoietic disorders

Shen Y. et al, (2025)

INCA033989: the first shot on goal for MPNs?

Benlabiod C. and Psaila B., (2024), Blood, 144, 2278 - 2279

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis

O'Sullivan J. et al, (2024), British Journal of Haematology

The fetal specific gene LIN28B is essential for human fetal b-lymphopoiesis and initiation of KMT2A-AFF1+ infant acute lymphoblastic leukemia

Ling R. et al, (2024), Blood, 144, 199 - 199

A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis

Li R. et al, (2024), Science Translational Medicine, 16

The fetal specific geneLIN28Bis essential for human fetal B-lymphopoiesis and initiation of KMT2A::AFF1 infant leukemia

Ling R. et al, (2024)

Generating human bone marrow organoids for disease modeling and drug discovery

Olijnik A-A. et al, (2024), Nature Protocols

Interim Analysis of Promise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib

Mead AJ. et al, (2024), BLOOD, 144, 3186 - 3187

Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort

Rampotas A. et al, (2024), BLOOD, 144, 1804 - 1806

RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study

Brierley CK. et al, (2024), BLOOD, 144, 3146 - 3147

Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A.

Brierley CK. et al, (2023), bioRxiv

The management of myelofibrosis: A British Society for Haematology Guideline.

McLornan DP. et al, (2023), British journal of haematology

Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.

McLornan DP. et al, (2023), British journal of haematology

Outcomes and Characteristics of Non-Melanoma Skin Cancers in Patients with Myeloproliferative Neoplasms on Ruxolitinib.

Rampotas A. et al, (2023), Blood

Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.

Rodriguez-Meira A. et al, (2023), Nat Genet

Data from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Data from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 1 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 1 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 2 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Load More